[Pharmacokinetic profile of silodosin in clinical practice].
Shimizu
Tomoji
T
Clinical Development Planning, Planning & Management Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan. tomoji_shimizu@pharm.kissei.co.jp
Miyashita
Itaru
I
Matsubara
Yasuhito
Y
Ikeda
Mitsugu
M
Yamaguchi
Masayuki
M
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism; D001682:Biological Availability; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D004347:Drug Interactions; D018565:Food-Drug Interactions; D006160:Guanosine Triphosphate / Q000502:physiology; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*; D007674:Kidney Diseases / Q000378:metabolism; D008297:Male; D009961:Orosomucoid / Q000378:metabolism; D011485:Protein Binding
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D007211:Indoles; D009961:Orosomucoid; D006160:Guanosine Triphosphate; D003577:Cytochrome P-450 Enzyme System; C095285:silodosin; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A